• Furkan Ali Uygur, Esra Dişçi, Rıfat Peksöz, Nurinnisa Öztürk, Mehmet İlhan Yildirgan, and Yavuz Albayrak.
• Muş State Hospital, Department of General Surgery - Muş, Turkey.
• Rev Assoc Med Bras (1992). 2022 Jul 1; 68 (7): 888-892.

ObjectiveGastric cancer ranks the third among the cancer-related deaths. It is diagnosed at advanced stage in many patients due to malignant proliferation and has a poor prognosis. Currently, no instrument or biomarker has been proven to diagnose the disease before the advanced stages. This study aimed to measure the serum levels of galanin and obestatin, which were examined in various studies including cancer studies, and to discuss their diagnostic value in gastric cancers.MethodsIn this study, 30 adult patients with gastric cancer and 30 healthy adults in the control group were examined prospectively. The demographic characteristics and serum levels of galanin and obestatin in the patient and control groups were recorded.ResultsThe mean serum level of galanin in the patient and control groups was 19.73±5.04 and 35.59±10.94 pg/mL, respectively. The mean serum level of obestatin in the patient and control groups was 40.21±5.82 and 15.15±3.32 ng/mL, respectively. A significant difference was found between the groups (p<0.001).ConclusionSerum levels of galanin were lower and serum levels of obestatin were higher in patients with gastric cancer compared to the healthy individuals. Serum levels of obestatin and galanin can be used as potential biomarkers in the diagnosis of gastric cancer.

10 keywords...

hide…